Collaborations

R&D Collaborations

InvivoGen Therapeutics has established several ongoing research and development collaborations within the Cancer-Bio-Health Cluster of Toulouse.

CRCT - INSERM U1037 (Toulouse - France)
Louis Buscail, PU-PH, Team Leader "molecular markers and biotherapy of digestive system cancers" at the Cancer Research Center, Toulouse Purpan (UMR 1037 Inserm / UPS / CNRS), InvivoGen Therapeutics and the National Institute of Health and Medical Research (UMR 858, now UMR 1037 since January 1st, 2011) are working together since 2000 regarding the development of a genetic therapy strategy for the treatment of pancreatic cancer. This strategy is based on the transfer of a hybrid suicide gene dck::umk and a type 2 somatostatin (sst2) receptor gene coupled with the chemotherapeutic agent Gemcitabine. InvivoGen Therapeutics and Toulouse University Hospital Center (CHU de Toulouse) have launched a phase I/II clinical trial to test this strategy (THERGAP trial) at the end of 2010 (Promoter CHU de Toulouse – Principal Investigator Prof. Louis BUSCAIL).

GIMAP EA3064 (Saint-Etienne - France)
InvivoGen Therapeutics has initiated a collaboration with the joint research unit GIMAP EA3064 for the development of immunoglobulin A (IgA) as research reagents and therapeutic agents. Therapeutics aspects cover HIV and oral vaccine research.


Manufacturing Agreements
CHU Toulouse
InvivoGen Therapeutics has signed a contract with the Toulouse University Hospital Center (Centre Hospitalier Universitaire - CHU Toulouse) to manufacture clinical lots for the TherGAP clinical trial (pancreatic cancer).


Licensing Agreements
Transgene
InvivoGen Therapeutics has granted Transgene an exclusive license with covering the use of the fcy::fur suicide gene for gene therapy of 5-FU sensitive tumors.
Copyright © InvivoGen Therapeutics - Site Map - Contacts - Design & Communication : www.netvizion.fr